Structure Therapeutics Inc. (GPCR) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $21.00K; Additional Paid in CapitalUSD $2.01B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-3.44M; Retained Earnings (Accumulated Deficit)USD $-652.43M.
- 2026-03-31: Common Stock, Value, IssuedUSD $21.00K; Additional Paid in CapitalUSD $2.00B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-2.19M; Retained Earnings (Accumulated Deficit)USD $-546.27M.
- 2025-12-31: Common Stock, Value, IssuedUSD $21.00K; Additional Paid in CapitalUSD $1.99B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $1.05M; Retained Earnings (Accumulated Deficit)USD $-470.30M.
- 2025-09-30: Common Stock, Value, IssuedUSD $18.00K; Additional Paid in CapitalUSD $1.27B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $825.00K; Retained Earnings (Accumulated Deficit)USD $-503.30M.
Structure Therapeutics Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $21.00K | $2.01B | $-3.44M | $-652.43M | $1.35B | 3 month · $12.63M | (m) |
| 2026-03-31 | $21.00K | $2.00B | $-2.19M | $-546.27M | $1.45B | 3 month · $11.64M | (m) |
| 2025-12-31 | $21.00K | $1.99B | $1.05M | $-470.30M | $1.52B | 12 month · $28.99M | (m) |
| 2025-09-30 | $18.00K | $1.27B | $825.00K | $-503.30M | $770.02M | 3 month · $7.50M | (m) |
| 2025-06-30 | $17.00K | $1.21B | $362.00K | $-437.59M | $772.08M | 3 month · $7.51M | (m) |
| 2025-03-31 | $17.00K | $1.20B | $815.00K | $-375.93M | $824.64M | 3 month · $5.92M | (m) |
| 2024-12-31 | $17.00K | $1.19B | $914.00K | $-329.10M | $864.84M | 12 month · $18.79M | (m) |
| 2024-09-30 | $17.00K | $1.19B | $2.84M | $-292.62M | $896.80M | 3 month · $6.02M | (m) |
| 2024-06-30 | $17.00K | $1.18B | $-487.00K | $-258.64M | $921.03M | 3 month · $4.20M | (m) |
| 2024-03-31 | $14.00K | $662.50M | $-90.00K | $-232.61M | $429.82M | 3 month · $2.74M | (m) |
| 2023-12-31 | $14.00K | $659.00M | $521.00K | $-206.57M | $452.97M | 12 month · $8.19M | (m) |
| 2023-09-30 | (m) | $375.33M | $-310.00K | $-182.07M | $192.96M | 3 month · $1.86M | (m) |
| 2023-06-30 | (m) | $373.00M | $-390.00K | $-158.21M | $214.41M | 3 month · $1.70M | (m) |
| 2023-03-31 | $11.00K | $371.12M | $147.00K | $-134.93M | $236.35M | 3 month · $2.53M | (m) |
| 2022-12-31 | $1.00K | $1.92M | $-110.00K | $-116.95M | $-115.14M | 12 month · $2.51M | 12 month · $1.51M |
| 2022-09-30 | (m) | (m) | (m) | (m) | $-103.91M | 3 month · $628.00K | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | $-92.10M | 3 month · $643.00K | 3 month · $1.51M |
| 2022-03-31 | (m) | (m) | (m) | (m) | $-77.23M | 3 month · $620.00K | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) | $-64.73M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |